Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: Assessment of different filter systems

Anesthesia and Analgesia

Volumn 91, Issue 2, 2000, Pages 265-269

  Koster, Andreas ^a   Merkle, Frank ^a   Hansen, Roland ^b   Loebe, Mathias ^a   Kuppe, H Herrmann ^a   Hetzer, Roland ^a   Crystal, George J ^c   Mertzlufft, Fritz ^d  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF ILLINOIS   (United States)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT HIRUDIN;

ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; DRUG ELIMINATION; DRUG HALF LIFE; HEMOFILTRATION; IN VITRO STUDY; KIDNEY FUNCTION; PLASMAPHERESIS; PRIORITY JOURNAL; THROMBOCYTOPENIA; ULTRAFILTRATION;

EID: 0033863121     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/00000539-200008000-00003     Document Type: Article

References (16)

1. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
2. Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin
3. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass: Assessment of the whole blood ecarin clotting time
4. Cardiovascular surgery without cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II using anticoagulation with recombinant hirudin
5. Cardiopulmonary bypass with recombinant hirudin in patients with heparin-induced thrombocytopenia type II: A synopsis of 19 cases
6. Prolonged bleeding after cardiopulmonary bypass with recombinant hirudin in heart transplantation
7. Bleeding complications associated with r-hirudin application for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II
8. Pharmacology of r-hirudin in renal impairment
9. Clinical pharmacology of recombinant hirudin
10. Pharmacokinetics of recombinant hirudin in haemodialyzed end-stage renal failure patients
11. High-volume, zero-balanced hemofiltration to reduce delayed inflammatory response to cardiopulmonary bypass in children
12. Influence of combined zero-balanced and modified ultrafiltration on the systemic inflammatory response during coronary artery bypass grafting
13. Hirudin as anticoagulant in experimental hemodialysis
14. In vitro study of r-hirudin permeability through membranes of different haemodialysers
15. Hirudin elimination by hemofiltration: A comparative in vitro study of different membranes
16. The structure of a complex of recombinant hirudin and human alpha-thrombin